908 Devices to Participate in the Stifel 2026 Healthcare Conference
908 Devices to Participate in the Stifel 2026 Healthcare Conference
908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today announced that management will participate in a fireside chat at the Stifel 2026 Healthcare Conference on Wednesday, November 11, 2026 at 4:00 p.m. ET.
A live webcast of the fireside chat will be available in the “Investors” section of the company’s website at: www.908devices.com. An archived replay will be available on the company’s website following the event.
About 908 Devices
908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers in vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learning. For more information, visit www.908devices.com.
Matt Roache
VP, Investor Relations
mroache@908devices.com
www.908devices.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20261104520044/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

7 Undervalued Stocks That Crushed Earnings

This Newly Undervalued Stock Has Plenty of Growth Ahead

The 10 Best Dividend Stocks
